CHU d Angers

Running trials

• Recruiting

  Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab)

  NCT07570589· Source

• Recruiting

  The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France

  NCT07211126· Source

• Recruiting

  Study of Alloknesia in Atopic Dermatitis

  NCT06923202· Source

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Source

• Recruiting

  Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients

  NCT06481813· Source

• Recruiting

  Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology

  NCT06392997· Source

• Recruiting

  Personalized Medicine for Advanced Biliary Cancer Patients

  NCT05615818· Phase 3· Source

• Recruiting

  A Study of Pitolisant in Patients With Prader-Willi Syndrome

  NCT06366464· Phase 3· Source

• Recruiting

  Optimization of the Surgical Care Pathway for Kidney Tumors by Digitizing Perioperative Nursing Coordination (UroCCR 126)

  NCT06047600· Source

• Active, not recruiting

  Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)

  NCT05768711· Phase 2· Source

• Recruiting

  Effect on Pre-operative Anxiety of a Personalized Three-dimensional Kidney Model Prior to Nephron-sparing Surgery- Rein 3D Anxiety

  NCT06035211· Source

• Recruiting

  Rheopheresis as Adjuvant Treatment of Calciphylaxis

  NCT04654000· Source

• Recruiting

  AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

  NCT05198960· Phase 3· Source

• Active, not recruiting

  Amyloidosis TTR Flow Reserve Evaluation

  NCT05103943· Source

• Active, not recruiting

  Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

  NCT04802590· Phase 2· Source

• Recruiting

  Cardiovascular and Venous Thromboembolism Disease in Patients with Von Willebrand Disease in the French West

  NCT05773638· Source

• Active, not recruiting

  PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS

  NCT04664465· Source

• Active, not recruiting

  Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

  NCT04070443· Phase 2· Source

• Active, not recruiting

  A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy

  NCT04023526· Phase 2· Source

• Active, not recruiting

  ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer

  NCT03570021· Phase 3· Source

• Recruiting

  IDMet (RaDiCo Cohort) (RaDiCo-IDMet)

  NCT05945576· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Kidney cancer2 recruiting
• Acute myeloid leukemia1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Atrial fibrillation1 recruiting
• Cervical cancer1 recruiting
• Chronic kidney disease1 recruiting
• Endometriosis1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lung cancer1 recruiting
• Myasthenia gravis1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Ovarian cancer1 recruiting
• Type 1 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Withdrawn

  Home Monitoring of Adult Patients With SMA: a Pilot Multicenter Validation Study

  NCT05839145· Source

• Completed

  Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis

  NCT05642208· Phase 4· Source

• Completed

  Partial Nephrectomy in Low Pressure

  NCT05404685· Source

• Terminated

  Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

  NCT05079230· Phase 3· Source

• Completed

  Virtual Reality for the Mitigation of Anxiety During Intrathecal Administration in Participants With Spinal Muscular Atrophy

  NCT05354414· Source

• Completed

  Effect of Increased Oxytocin Doses on the Mode of Delivery in Obese Primiparous Women With Spontaneous or Induced Labour

  NCT04760496· Phase 4· Source

• Terminated

  Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

  NCT04778397· Phase 3· Source

• Completed

  Screening of Liver Fibrosis Using Blood Tests in Patients With Type 2 Diabetes Mellitus

  NCT04232293· Source

• Withdrawn

  A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)

  NCT04264806· Phase 2· Source

• Completed

  BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS

  NCT04827719· Phase 2· Source

• Terminated

  Assessment of Quitting Versus Using Aspirin Therapy In Patients Treated With Oral Anticoagulation for Atrial Fibrillation or Other Indication With Stabilized Coronary Artery Disease

  NCT04217447· Phase 3· Source

• Completed

  SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)

  NCT03806452· Phase 2· Source

• Completed

  Simultaneous Portal and Hepatic Vein Versus Portal Vein Embolizations for Hypertrophy of the Future Liver Remnant

  NCT03841305· Phase 2· Source

• Completed

  Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms

  NCT03808805· Phase 3· Source

• Completed

  Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)

  NCT03591731· Phase 2· Source

• Completed

  Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis

  NCT03445845· Phase 4· Source

• Terminated

  Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial Injection of Idarubicin/Lipiodol Emulsion

  NCT03727633· Phase 2· Source

• Completed

  FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation

  NCT03584711· Phase 2· Source

• Completed

  Quality of Sleep of Patients With Predominant Central Sleep Apnea Syndrome(SAS) Whose EF > 45% Treated by ASV

  NCT02835638· Source

• Completed

  PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA

  NCT03006432· Phase 3· Source

• Completed

  Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance

  NCT02896582· Phase 2· Source

• Completed

  Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk

  NCT02757989· Source

• Completed

  R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL

  NCT01865110· Phase 3· Source